The HSP90 inhibitor 17-AAG potentiates the antileishmanial activity of the ether lipid edelfosine

Acta Tropica

Volumn 131, Issue 1, 2014, Pages 32-36

  Varela M, Rubén E ^a   Mollinedo Gajate, Cristina ^a   Muro, Antonio ^a   Mollinedo, Faustino ^a  

^a UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

17 AAG; Apoptosis like cell death; Cell cycle arrest; Edelfosine; HSP90 inhibitor; Leishmania spp.

Indexed keywords

EDELFOSINE; HEAT SHOCK PROTEIN 90; TANESPIMYCIN;

LEISHMANIASIS; PARASITE; PHOSPHOLIPID; PROTEIN; SURVIVAL;

ANTIPROTOZOAL ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE G0 PHASE; CONTROLLED STUDY; DRUG POTENTIATION; G1 PHASE CELL CYCLE CHECKPOINT; LEISHMANIA; LEISHMANIA INFANTUM; LEISHMANIA PANAMENSIS; NONHUMAN; PROMASTIGOTE;

17-AAG; APOPTOSIS-LIKE CELL DEATH; CELL CYCLE ARREST; EDELFOSINE; HSP90 INHIBITOR; LEISHMANIA SPP.;

APOPTOSIS; BENZOQUINONES; CULTURE MEDIA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; G0 PHASE; G1 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION; HSP90 HEAT-SHOCK PROTEINS; LACTAMS, MACROCYCLIC; LEISHMANIA; LEISHMANIA INFANTUM; PHOSPHOLIPID ETHERS; PROTOZOAN PROTEINS;

EID: 84890836937     PISSN: 0001706X     EISSN: 18736254     Source Type: Journal    
DOI: 10.1016/j.actatropica.2013.11.018     Document Type: Article

References (31)

1. Azzouz S., Maache M., Dos Santos M.F., Sarciron M.E., Petavy A.F., Osuna A. Aspects of the cytological activity of edelfosine, miltefosine, and ilmofosine in Leishmania donovani. J. Parasitol. 2006, 92:877-883.
2. Azzouz S., Maache M., Garcia R.G., Osuna A. Leishmanicidal activity of edelfosine, miltefosine and ilmofosine. Basic Clin. Pharmacol. Toxicol. 2005, 96:60-65.
3. Brandau S., Dresel A., Clos J. High constitutive levels of heat-shock proteins in human-pathogenic parasites of the genus Leishmania. Biochem. J. 1995, 310(Pt 1):225-232.
4. Croft S.L., Seifert K., Duchene M. Antiprotozoal activities of phospholipid analogues. Mol. Biochem. Parasitol. 2003, 126:165-172.
5. David-Cordonnier M.H., Gajate C., Olmea O., Laine W., de la Iglesia-Vicente J., Perez C., Cuevas C., Otero G., Manzanares I., Bailly C., Mollinedo F. DNA and non-DNA targets in the mechanism of action of the antitumor drug trabectedin. Chem. Biol. 2005, 12:1201-1210.
6. Gajate C., Del Canto-Janez E., Acuna A.U., Amat-Guerri F., Geijo E., Santos-Beneit A.M., Veldman R.J., Mollinedo F. Intracellular triggering of Fas aggregation and recruitment of apoptotic molecules into Fas-enriched rafts in selective tumor cell apoptosis. J. Exp. Med. 2004, 200:353-365.
7. Gajate C., Mollinedo F. Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts. Blood 2007, 109:711-719.
8. 3-induced apoptosis of human leukemic cells. Int. J. Cancer 2000, 86:208-218.
9. George P., Bali P., Annavarapu S., Scuto A., Fiskus W., Guo F., Sigua C., Sondarva G., Moscinski L., Atadja P., Bhalla K. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood 2005, 105:1768-1776.
10. Katragadda U., Fan W., Wang Y., Teng Q., Tan C. Combined delivery of paclitaxel and tanespimycin via micellar nanocarriers: pharmacokinetics, efficacy and metabolomic analysis. PLoS One 2013, 8:e58619.
11. Li Q., Zhou Y., Yao C., Ma X., Wang L., Xu W., Wang Z., Qiao Z. Apoptosis caused by Hsp90 inhibitor geldanamycin in Leishmania donovani during promastigote-to-amastigote transformation stage. Parasitol. Res. 2009, 105:1539-1548.
12. Lopez Kostka S., Dinges S., Griewank K., Iwakura Y., Udey M.C., von Stebut E. IL-17 promotes progression of cutaneous leishmaniasis in susceptible mice. J. Immunol. 2009, 182:3039-3046.
13. Lux H., Heise N., Klenner T., Hart D., Opperdoes F.R. Ether-lipid (alkyl-phospholipid) metabolism and the mechanism of action of ether-lipid analogues in Leishmania. Mol. Biochem. Parasitol. 2000, 111:1-14.
14. Mollinedo F., de la Iglesia-Vicente J., Gajate C., Estella-Hermoso de Mendoza A., Villa-Pulgarin J.A., Campanero M.A., Blanco-Prieto M.J. Lipid raft-targeted therapy in multiple myeloma. Oncogene 2010, 29:3748-3757.
15. Mollinedo F., de la Iglesia-Vicente J., Gajate C., Estella-Hermoso de Mendoza A., Villa-Pulgarin J.A., de Frias M., Roue G., Gil J., Colomer D., Campanero M.A., Blanco-Prieto M.J. In vitro and in vivo selective antitumor activity of edelfosine against mantle cell lymphoma and chronic lymphocytic leukemia involving lipid rafts. Clin. Cancer Res. 2010, 16:2046-2054.
16. L. Cancer Res. 1997, 57:1320-1328.
17. Mollinedo F., Gajate C., Morales A.I., del Canto-Janez E., Justies N., Collia F., Rivas J.V., Modolell M., Iglesias A. Novel anti-inflammatory action of edelfosine lacking toxicity with protective effect in experimental colitis. J. Pharmacol. Exp. Ther. 2009, 329:439-449.
18. Neckers L. Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol. Med. 2002, 8:S55-S61.
19. Neckers L., Workman P. Hsp90 molecular chaperone inhibitors: are we there yet?. Clin. Cancer Res. 2012, 18:64-76.
20. Nieto-Miguel T., Gajate C., Gonzalez-Camacho F., Mollinedo F. Proapoptotic role of Hsp90 by its interaction with c-Jun N-terminal kinase in lipid rafts in edelfosine-mediated antileukemic therapy. Oncogene 2008, 27:1779-1787.
21. Peacock C.S., Seeger K., Harris D., Murphy L., Ruiz J.C., Quail M.A., Peters N., Adlem E., Tivey A., Aslett M., Kerhornou A., Ivens A., Fraser A., Rajandream M.A., Carver T., Norbertczak H., Chillingworth T., Hance Z., Jagels K., Moule S., Ormond D., Rutter S., Squares R., Whitehead S., Rabbinowitsch E., Arrowsmith C., White B., Thurston S., Bringaud F., Baldauf S.L., Faulconbridge A., Jeffares D., Depledge D.P., Oyola S.O., Hilley J.D., Brito L.O., Tosi L.R., Barrell B., Cruz A.K., Mottram J.C., Smith D.F., Berriman M. Comparative genomic analysis of three Leishmania species that cause diverse human disease. Nat. Genet. 2007, 39:839-847.
22. Petersen A.L., Guedes C.E., Versoza C.L., Lima J.G., de Freitas L.A., Borges V.M., Veras P.S. 17- AAG kills intracellular Leishmania amazonensis while reducing inflammatory responses in infected macrophages. PLoS One 2012, 7:e49496.
23. Queitsch C., Sangster T.A., Lindquist S. Hsp90 as a capacitor of phenotypic variation. Nature 2002, 417:618-624.
24. Rebbe N.F., Ware J., Bertina R.M., Modrich P., Stafford D.W. Nucleotide sequence of a cDNA for a member of the human 90-kDa heat-shock protein family. Gene 1987, 53:235-245.
25. Silva K.P., Seraphim T.V., Borges J.C. Structural and functional studies of Leishmania braziliensis Hsp90. Biochim. Biophys. Acta 2013, 1834:351-361.
26. Tasew G., Nylen S., Lieke T., Lemu B., Meless H., Ruffin N., Wolday D., Asseffa A., Yagita H., Britton S., Akuffo H., Chiodi F., Eidsmo L. Systemic FasL and TRAIL neutralisation reduce leishmaniasis induced skin ulceration. PLoS Negl. Trop. Dis. 2010, 4:e844.
27. Usmani S.Z., Bona R., Li Z. 17 AAG for HSP90 inhibition in cancer-from bench to bedside. Curr. Mol. Med. 2009, 9:654-664.
28. Varela-M R.E., Villa-Pulgarin J.A., Yepes E., Muller I., Modolell M., Munoz D.L., Robledo S.M., Muskus C.E., Lopez-Aban J., Muro A., Velez I.D., Mollinedo F. In vitro and in vivo efficacy of ether lipid edelfosine against Leishmania spp. and SbV-resistant parasites. PLoS Negl. Trop. Dis. 2012, 6:e1612.
29. Whitesell L., Lindquist S.L. HSP90 and the chaperoning of cancer. Nat. Rev. Cancer 2005, 5:761-772.
30. Wiesgigl M., Clos J. Heat shock protein 90 homeostasis controls stage differentiation in Leishmania donovani. Mol. Biol. Cell 2001, 12:3307-3316.
31. Wiesgigl M., Clos J. The heat shock protein 90 of Leishmania donovani. Med. Microbiol. Immun. 2001, 190:27-31.